Last Updated: April 5, 2023
EBV-associated lymphomas are a heterogeneous group of aggressive B-, T-, and NK- cell malignancies.
Last Updated: April 5, 2023
Epstein-Barr virus (EBV) is an oncogenic herpesvirus associated with multiple cancers, including Burkitt lymphoma, Hodgkin lymphoma, primary central nervous system lymphoma and post-transplant
Last Updated: April 5, 2023
Classic Hodgkin lymphoma (HL) is an aggressive malignancy with a peak incidence in adolescents and young adults.
Funding Sources
- Targeting Latency Switch in EBV Lymphomas awarded by National Cancer Institute Principal Investigator 2022 - 2027
- Defining the evolution and tumor microenvironment interactions of classic Hodgkin lymphoma through single-cell multi-omics and genetically engineered mouse models awarded by Starr Cancer Consortium Principal Investigator 2022 - 2024
- Biomarkers Predictive of Antitumor Response in Primary Mediastinal B-cell Lymphoma awarded by Children''s Oncology Group Principal Investigator 2022 - 2023
- Risk Stratification using Tumor Microenviroment Signatures in Hodgkin Lymphoma awarded by Children''s Oncology Group Principal Investigator 2022 - 2023
- B cell determinants of EBV latency awarded by National Cancer Institute Co-Principal Investigator 2022 - 2027
- Assessment of Clonal Hematopoiesis and Its Relationship to Cardiovascular Disease in Hodgkin Lymphoma Survivors awarded by United States Department of Defense Principal Investigator Subaward 2022 - 2026
- An Integrative Radiogenomic Framework for Predicting Treatment Failure in Adolescents & Young Adults with Hodgkin Lymphoma awarded by United States Department of Defense Principal Investigator Subaward 2022 - 2026
- COG UG1CA233249 Subaward Number: AR64029 PO: 0000004794 awarded by National Cancer Institute Principal Investigator Subaward 2022 - 2024
- COG U10CA180886 PO: 0000003744 awarded by National Cancer Institute Principal Investigator Subaward 2022 - 2023
- Targeting latent viral antigens in EBV+ Burkitt Lymphoma awarded by Hyundai Hope on Wheels Foundation Principal Investigator 2021 - 2023
- Modulation Of Viral Latency In EBV Lymphomas To Sensitize Tumors To Immunotherapy awarded by American Society of Hematology Inc Principal Investigator 2021 - 2023
- AHO1822 Study Chair awarded by Merck & Co., Inc. Principal Investigator Subaward 2020 - 2025